Physician profile
Eric G Wikler
NPI 1992889364
$3,288.83
in general payments reported to CMS, 2019-2025
36 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $353 · 2021: $553 · 2022: $416 · 2023: $487 · 2024: $583 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.37 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.78 | 2021-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.66 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $308.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $265.63 | 2019-2024 | Veozah |
| Lilly USA, LLC | $210.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $203.72 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.05 | 2019-2024 | Trulance, Xifaxan |
| Pfizer INC. | $151.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $134.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $130.35 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $94.79 | 2020-2025 | Airsupra, Farxiga |
| Amgen INC. | $66.46 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $57.07 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $56.70 | 2019-2025 | Eliquis |
| Allergan, INC. | $55.14 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47.46 | 2022-2023 | |
| Amarin Pharma, INC. | $45.51 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $43.34 | 2021 | |
| Dexcom, INC. | $42.19 | 2023-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $35.06 | 2019-2022 | |
| Lundbeck LLC | $34.67 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $34.07 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $33.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.26 | 2021-2022 | |
| Exact Sciences Corporation | $28.72 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $26.13 | 2020 | |
| Gilead Sciences, INC. | $24.71 | 2022 | |
| Boston Scientific Corporation | $24.06 | 2021 | |
| Eisai INC. | $19.20 | 2021 | |
| Lucid Diagnostics INC. | $18.25 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.76 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.44 | 2021 | |
| Braintree Laboratories, INC. | $13.29 | 2019 | |
| Bardy Diagnostics, INC. | $12.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wikler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.